The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 934 GLP-1 Medications articles
Novo Nordisk's Wegovy is now available in Malaysia, offering a powerful GLP-1 option for adults with obesity or overweight conditions. With 54.4% of Malaysian adults affected, this once-weekly injection mimics gut hormones to regulate appetite. Medical experts emphasize combining it with diet, exercise, and lifestyle changes for optimal results.
A new book, 'Off the Scales,' reveals how Ozempic and GLP-1 drugs are reshaping societal views on obesity. Author Aimee Donnellan details their development, profound weight loss effects, and the urgent need for medical approaches to this growing crisis. Learn why these therapies mark a turning point in weight management.
Bollywood actress Bhumi Pednekar lost 40kg without Ozempic or injectables, despite constant rumors. She attributes her transformation to disciplined workouts, a balanced vegetarian diet, and recovery from severe dengue. Discover her practical tips for real weight management.
AbbVie is bolstering its obesity portfolio with GUBamy, an amylin-based drug from Gubra as a GLP-1 alternative. Unlike gut hormone-mimicking GLP-1s like Wegovy and Zepbound, amylin targets pancreatic hormones for improved tolerability and muscle retention. The company eyes long-term efficacy amid a $150B market boom.
The new FDA-approved Wegovy pill offers the same weight loss benefits as injections but in a daily oral dose. Dr. Drew Payne explains why higher doses are needed due to GI absorption and how both achieve 15% average weight loss. Costs drop significantly, making treatment more affordable.
Weight loss drugs like GLP-1 medications are transforming consumer spending patterns. New Circana research reveals users cut grocery costs by 2% but increase outlays on beauty and self-care items. Protein-focused products surge 40% as users combat muscle loss side effects.
The first oral GLP-1 for weight loss, Wegovy pill, is now available in New Jersey stores. One in eight adults have tried GLP-1 meds, with 20% interested per KFF data. Discover where to buy, costs, and safety info.
Hims & Hers investment narrative shifts amid legal scrutiny on compounded GLP-1 agonists. A January 2026 antitrust lawsuit accuses Eli Lilly and Novo Nordisk of blocking compounded Mounjaro and Wegovy. This raises uncertainties for telehealth providers reliant on these affordable weight management options.
GLP-1 medications are revolutionizing not just weight loss but how people approach food, prioritizing protein quality over quantity. Research shows users eat less overall, including less meat, yet value nutrient-dense proteins more highly. These changes signal premiumization in the food sector and broader economic impacts. (~198 chars)
